Preoperative Avapritinib for Localized PDGFRA-Mutant GIST: Marked Pathologic Response, but Limited Feasibility at Standard Dosing.

Ranjbarian T, Antkowiak M, Sarno S, Kato S, Burgoyne AM, Mayo SC, Heinrich MC, Fanta PT, Sicklick JK

DOI: 10.1002/cam4.72100
Published: 2026 Aug
Container: Cancer medicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/cam4.72100,
  title = {Preoperative Avapritinib for Localized PDGFRA-Mutant GIST: Marked Pathologic Response, but Limited Feasibility at Standard Dosing.},
  author = {Ranjbarian T and Antkowiak M and Sarno S and Kato S and Burgoyne AM and Mayo SC and Heinrich MC and Fanta PT and Sicklick JK},
  year = {2026},
  journal = {Cancer medicine},
  doi = {10.1002/cam4.72100},
  url = {https://doi.org/10.1002/cam4.72100}
}

RIS

TY  - JOUR
TI  - Preoperative Avapritinib for Localized PDGFRA-Mutant GIST: Marked Pathologic Response, but Limited Feasibility at Standard Dosing.
AU  - Ranjbarian T
AU  - Antkowiak M
AU  - Sarno S
AU  - Kato S
AU  - Burgoyne AM
AU  - Mayo SC
AU  - Heinrich MC
AU  - Fanta PT
AU  - Sicklick JK
PY  - 2026
JO  - Cancer medicine
DO  - 10.1002/cam4.72100
UR  - https://doi.org/10.1002/cam4.72100
ER  -

APA

T, R., M, A., S, S., S, K., AM, B., SC, M., MC, H., PT, F., & JK, S. (2026). Preoperative Avapritinib for Localized PDGFRA-Mutant GIST: Marked Pathologic Response, but Limited Feasibility at Standard Dosing.. Cancer medicine. https://doi.org/10.1002/cam4.72100

Source records

pubmed · retrieved 2026-09-25T13:39:24.238Z